AI assistant
BeOne Medicines Ltd. — Director's Dealing 2019
Jul 2, 2019
30073_dirs_2019-07-01_a022a756-0c8f-467d-9776-25fcc3e9e807.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2019-06-27
Reporting Person: Liang Howard (CFO & Chief Strategy Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-06-27 | Ordinary Shares | S | 5876 | $9.4712 | Disposed | 122317 | Direct |
Footnotes
F1: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person.
F2: The price reported in Column 4 is a weighted average price per ordinary share. One ordinary share equals 1/13 American Depositary Share. These shares were sold in multiple transactions at prices ranging from $9.188 to $9.5269, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price.